{"gene":"CYP3A4","run_date":"2026-06-09T22:57:19","timeline":{"discoveries":[{"year":2003,"finding":"HNF4α is required for PXR- and CAR-mediated transcriptional activation of CYP3A4. A specific cis-acting element in the CYP3A4 gene enhancer confers HNF4α binding, which then permits PXR- and CAR-mediated gene activation. Conditional hepatic deletion of Hnf4α in mice reduced basal and inducible CYP3A expression.","method":"Reporter gene assays, electrophoretic mobility shift assay (EMSA), conditional knockout mice (Hnf4α deletion), cell-based transfection","journal":"Nature medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal reporter assays, EMSA identifying cis-element, in vivo conditional KO validation; multiple orthogonal methods in a single rigorous study","pmids":["12514743"],"is_preprint":false},{"year":2002,"finding":"CAR (constitutive androstane receptor) trans-activates CYP3A4 expression both in vitro and in vivo. CAR responsiveness is mediated by two high-affinity binding motifs at approximately −7720 and −150 bases upstream of the transcription start site. These same CAR response elements also mediate PXR-mediated trans-activation, indicating cooperative interplay between CAR and PXR in CYP3A4 regulation.","method":"Reporter gene assays in cell lines, in vivo studies, identification of CAR binding motifs in CYP3A4 5'-flanking region","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro and in vivo evidence, identified specific binding motifs, multiple orthogonal methods","pmids":["12130689"],"is_preprint":false},{"year":2010,"finding":"An intronic SNP in CYP3A4 (rs35599367, C>T in intron 6; designated CYP3A4*22) causes allelic expression imbalance in human liver. Livers with CC genotype have 1.7-fold higher mRNA and 2.5-fold higher enzyme activity compared to CT/TT carriers, with functional consequences for statin metabolism.","method":"Allelic CYP3A4 hnRNA and mRNA expression measurement in 76 human liver samples, minigene transfection in cell culture, pharmacokinetic analysis in 235 patients","journal":"The pharmacogenomics journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro minigene assay mechanistically linking SNP to expression, validated in human liver samples and clinical cohort; multiple orthogonal methods","pmids":["20386561"],"is_preprint":false},{"year":2016,"finding":"CYP3A4*22 (rs35599367 C>T in intron 6) reduces mRNA/protein expression by promoting formation of a nonfunctional alternative splice variant with partial intron 6 retention in liver but not in small intestines, demonstrating tissue-specific splicing as the mechanism of reduced expression.","method":"Human liver RNA analysis, CYP3A4 minigene transfection in HepG2 (liver) and LS-174T (intestinal) cell lines","journal":"Pharmacogenetics and genomics","confidence":"High","confidence_rationale":"Tier 2 / Strong — minigene functional assay with allele comparison, validated in human liver tissue, tissue-specificity confirmed with two cell lines","pmids":["26488616"],"is_preprint":false},{"year":2001,"finding":"CYP3A4 variant F189S exhibits lower turnover numbers for testosterone and chlorpyrifos, while L293P has higher turnover numbers for both substrates, compared to wild-type CYP3A4*1. Variants M445T and P467S showed no significant difference from wild-type in catalytic activity.","method":"Site-directed mutagenesis of cDNA, heterologous expression in E. coli, in vitro enzyme activity assay with testosterone and chlorpyrifos as substrates","journal":"The Journal of pharmacology and experimental therapeutics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with mutagenesis, multiple substrates tested, single lab","pmids":["11714865"],"is_preprint":false},{"year":2001,"finding":"Two CYP3A4 protein variants (R130Q and P416L) fail to produce detectable P450 holoprotein when expressed in bacteria. T363M is expressed at significantly lower levels than wild-type. L373F displays a significantly altered testosterone metabolite profile and a four-fold increase in Km for 1'-OH midazolam formation.","method":"Heterologous bacterial expression system, steroid hydroxylase activity assays, midazolam hydroxylation kinetics","journal":"Pharmacogenetics","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with multiple alleles characterized by activity assays, single lab","pmids":["11470997"],"is_preprint":false},{"year":2006,"finding":"CYP3A4*20 contains a premature stop codon yielding a truncated protein that does not incorporate heme and is completely devoid of catalytic activity. The heterozygous carrier showed low systemic midazolam clearance in vivo, confirming genotype-phenotype correlation.","method":"DNA sequencing, heterologous expression in yeast and HEK293 cells, in vivo midazolam pharmacokinetics (phenotyping)","journal":"Clinical pharmacology and therapeutics","confidence":"High","confidence_rationale":"Tier 1-2 / Moderate — heterologous expression demonstrating absent heme incorporation and zero catalytic activity, confirmed with in vivo pharmacokinetics","pmids":["16580902"],"is_preprint":false},{"year":2018,"finding":"A de novo missense mutation c.902T>C (p.I301T) in CYP3A4 alters substrate recognition site 4 (SRS-4) conformation. The mutant CYP3A4 oxidizes 1,25-dihydroxyvitamin D with 10-fold greater activity than wild-type CYP3A4, and 2-fold greater activity than CYP24A1, causing accelerated vitamin D inactivation and vitamin D-dependent rickets type 3.","method":"Whole exome sequencing, in vitro enzyme activity assay comparing mutant vs wild-type CYP3A4 activity toward vitamin D metabolites","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution showing 10-fold gain-of-function toward vitamin D metabolites, mutant structurally characterized at SRS-4, linked to clinical phenotype","pmids":["29461981"],"is_preprint":false},{"year":2009,"finding":"miR-27b directly targets the 3'-UTR of CYP3A4 and suppresses its protein expression by >30%. miR-27b also indirectly regulates CYP3A4 transcription by targeting the VDR 3'-UTR, reducing VDR levels. Disruption of the miRNA response element (MRE) within CYP3A4 3'UTR led to 2- to 3-fold increase in reporter activity.","method":"Luciferase reporter assays with CYP3A4 3'UTR, site-directed mutagenesis of MRE, immunoblot analysis, qPCR, overexpression of miR-27b in cell lines","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase reporter with MRE disruption plus immunoblot protein quantification, single lab, two orthogonal methods","pmids":["19581388"],"is_preprint":false},{"year":2007,"finding":"The circadian transcription factor DBP activates CYP3A4 transcription by binding to a DNA sequence near the transcription start site, driving rhythmic (~24 h) oscillation in CYP3A4 mRNA and metabolic activity. The negative circadian clock component E4BP4 represses DBP-mediated CYP3A4 transcription.","method":"Luciferase reporter gene analysis, electrophoretic mobility shift assay (EMSA), serum-shocked HepG2 cells as circadian model","journal":"Pharmacogenetics and genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA confirmed direct DBP binding to CYP3A4 promoter element, reporter assays demonstrated E4BP4 repression, single lab","pmids":["18004209"],"is_preprint":false},{"year":2000,"finding":"Both the glucocorticoid receptor (GR) and pregnane X receptor (PXR) mediate hydrocortisone-dependent induction of CYP3A4 via the −1 kb promoter region. PXR decreases the EC50 for hydrocortisone-dependent induction by 3.3-fold. Rifampicin-dependent activation favors PXR over GR.","method":"Reporter gene system with −1 kb CYP3A4 promoter in HepG2 cells, separate and combined transfection of hGR and hPXR expression plasmids","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-based reporter assay with receptor-specific transfection, dose-response analysis, single lab","pmids":["10772626"],"is_preprint":false},{"year":2003,"finding":"Transgenic mice carrying the human CYP3A4 upstream regulatory region linked to lacZ show that sequences beyond −3.2 kb are required for both constitutive expression and xenobiotic induction. PXR/CAR-activating reagents (dexamethasone, pregnenolone 16α-carbonitrile, phenobarbital) induce expression through the xenobiotic-responsive enhancer module (XREM, −7.2 to −7.8 kb). Induction operates primarily through zonal recruitment of more hepatocytes to expression.","method":"CYP3A4/lacZ transgenic mice, histochemical staining for β-galactosidase, deletion construct analysis","journal":"Molecular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo transgenic mouse model, deletion analysis defining required regulatory region, single lab","pmids":["12815159"],"is_preprint":false},{"year":2005,"finding":"Verapamil and its metabolite N-desalkylverapamil (D617) form a metabolic-intermediate complex (MIC) with CYP3A4 (characteristic 455 nm peak) but not with CYP3A5, demonstrating differential mechanism-based inhibition. Norverapamil inactivates CYP3A4 with kinact = 0.30 min−1 and KI = 10.3 μM, but inactivates CYP3A5 ~45-fold less efficiently.","method":"Dual beam spectrophotometry for MIC detection, time-dependent inhibition assays with cDNA-expressed CYP3A4 and CYP3A5, human liver microsomes","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct spectrophotometric detection of MIC, quantitative kinetics with recombinant enzymes and human liver microsomes, multiple orthogonal methods","pmids":["15689501"],"is_preprint":false},{"year":2010,"finding":"CYP3A4*16 (T185S, found in East Asians) exhibits considerably reduced intrinsic clearance (by 60–84%) for midazolam, carbamazepine, atorvastatin, paclitaxel, and irinotecan due to increased Km values, while CYP3A4*18 (L293P) shows reduced Vmax for midazolam, paclitaxel, docetaxel, and irinotecan with unchanged Km values. Both alleles show substrate-dependent effects.","method":"Heterologous expression in Sf21 insect cell microsomes with human NADPH-P450 reductase, kinetic assays with seven substrates","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with recombinant enzymes, kinetic parameters (Km, Vmax) for multiple substrates, single lab","pmids":["20847137"],"is_preprint":false},{"year":2015,"finding":"Citrate ions, which mimic anionic phospholipids of the microsomal membrane, bind CYP3A4 at a site near the N-terminus where it splits from the protein core, and stimulate CYP3A4 monooxygenase activity in a concentration-dependent manner. CYP3A4-substrate binding, NADPH-dependent reduction of CPR, and interflavin and interprotein electron transfer were identified as citrate-sensitive steps.","method":"X-ray co-crystallization of CYP3A4 with progesterone and citrate, functional assays of soluble CYP3A4/CPR reconstituted system, comparative analysis of anions","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — crystal structure identifying citrate-binding site plus functional reconstitution assay identifying mechanistic steps, single rigorous study","pmids":["26066995"],"is_preprint":false},{"year":2010,"finding":"Raloxifene undergoes CYP3A4-mediated dehydrogenation to a reactive diquinone methide intermediate (not via arene oxide), which forms adducts with a carboxylic acid moiety of CYP3A4 apoprotein, causing mechanism-based inactivation. 7-Hydroxyraloxifene is produced by hydrolysis from the putative ester conjugate rather than direct oxygenation.","method":"18O-incorporation studies with isotopically labeled substrates in reconstituted CYP3A4 system, mass spectrometry metabolite analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — 18O-isotope tracing with reconstituted enzyme, mechanistically distinguishes oxygenation vs dehydrogenation pathway, single rigorous study","pmids":["20405834"],"is_preprint":false},{"year":2012,"finding":"p53 directly binds p53-responsive elements in CYP3A4 regulatory DNA and enhances CYP3A4 transcription. Activation of p53 by chemotherapeutic agents (cisplatin, etoposide, doxorubicin) induces CYP3A4 expression and enzymatic activity in a p53-dependent manner in human hepatocytes.","method":"Microarray screen, chromatin immunoprecipitation (ChIP) for p53 binding to CYP3A4 regulatory regions, reporter gene assays, qPCR, enzymatic activity assays in HepG2, Huh6, and primary human hepatocytes","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP demonstrating direct p53 binding to CYP3A4 gene regulatory region, reporter gene assay, functional activity assay; single lab, multiple methods","pmids":["23054612"],"is_preprint":false},{"year":2011,"finding":"Metformin suppresses PXR-mediated CYP3A4 expression in human hepatocytes by disrupting PXR's interaction with steroid receptor coactivator-1 (SRC1), independently of the PXR ligand binding pocket. Metformin also inhibited VDR-, GR-, and CAR-mediated induction of CYP3A4. AMPK activation and SHP upregulation were not involved in this mechanism.","method":"Reporter gene assays, qRT-PCR in human hepatocytes, two-hybrid assay (PXR-SRC1 interaction), Pxr−/− mouse experiments","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — two-hybrid assay identifying disruption of PXR-SRC1 interaction as mechanism, in vivo Pxr−/− mouse validation, single lab, multiple methods","pmids":["21920351"],"is_preprint":false},{"year":2006,"finding":"CYP3A4 catalyzes the metabolic activation of pradefovir to its active antiviral form PMEA. This conversion is inhibited by ketoconazole and a monoclonal antibody specific to CYP3A4. In human liver microsomes, Km = 60 μM and Vmax = 228 pmol/min/mg protein. No other cDNA-expressed CYP isoform catalyzed this conversion.","method":"cDNA-expressed CYP isoforms panel, human liver microsomes with kinetic parameters, CYP3A4-specific inhibitors (ketoconazole and monoclonal antibody 3A4)","journal":"Antimicrobial agents and chemotherapy","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with CYP isoform panel and kinetics, antibody-based inhibition confirming CYP3A4 specificity, single lab","pmids":["16940083"],"is_preprint":false},{"year":2012,"finding":"VDR polymorphisms (BsmIG>A, Cdx2-3731G>A, GATA-1012A>G) are significantly associated with intestinal CYP3A4 expression and activity. Intestinal CYP3A4 expression shows seasonal variation, being significantly higher between April and September, likely related to annual changes in UV sunlight and vitamin D levels activating VDR-mediated transcription.","method":"Genotyping of VDR polymorphisms, CYP3A4 protein/mRNA measurement in intestinal biopsies, midazolam pharmacokinetics in patients","journal":"Biochemical pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct measurement of CYP3A4 expression linked to VDR genotype and seasonal variation, correlation with midazolam pharmacokinetics; single lab","pmids":["22484315"],"is_preprint":false},{"year":2022,"finding":"A distal regulatory region (DRR) physically interacts with the CYP3A4 promoter (detected by 4C chromatin conformation capture). CRISPR-mediated deletion of the DRR decreased expression of CYP3A4, CYP3A5, and CYP3A7, identifying it as a shared enhancer. Two SNPs (rs115025140 and rs776744/rs776742) within the DRR increase enhancer-driven transcription in reporter assays and are associated with increased CYP3A4/CYP3A5 expression in human liver.","method":"4C chromatin conformation capture, CRISPR deletion, luciferase reporter assays, CYP3A4 mRNA and protein measurement in human liver cohort (n=246)","journal":"Clinical and translational science","confidence":"High","confidence_rationale":"Tier 2 / Strong — 4C assay identifying physical promoter-enhancer interaction, CRISPR functional deletion, reporter assays, human liver cohort validation; multiple orthogonal methods","pmids":["36045613"],"is_preprint":false},{"year":2022,"finding":"Panaxytriol upregulates CYP3A4 expression by promoting PXR dissociation from HSP90α and enhancing PXR binding to RXRα, facilitating PXR nuclear translocation and transcriptional activation. At high concentrations, CAR undergoes a similar mechanism but generally antagonizes PXR binding to RXRα.","method":"Co-immunoprecipitation (PXR/CAR binding to RXRα and HSP90α), immunofluorescence for nuclear translocation, qPCR, western blot, siRNA silencing of hCAR","journal":"Phytomedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — co-IP demonstrating altered PXR-HSP90α and PXR-RXRα interactions, nuclear translocation confirmed, single lab, multiple methods","pmids":["35417848"],"is_preprint":false},{"year":2008,"finding":"Quetiapine is metabolized by CYP3A4 with substantially higher intrinsic clearance than by CYP3A5 (<35% relative activity). CYP3A5 produces a different metabolic pattern, with O-desalkylquetiapine constituting a higher proportion of metabolites. Coexpressed cytochrome b5 decreases CYP3A4 intrinsic clearance for quetiapine 3-fold but has no effect on CYP3A5 clearance.","method":"In vitro metabolism assays with CYP3A4 and CYP3A5 insect cell microsomes ± cytochrome b5, substrate depletion kinetics, metabolite identification","journal":"Drug metabolism and disposition","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution comparing recombinant CYP3A4 vs CYP3A5 with kinetics, cytochrome b5 effect characterized, single lab","pmids":["19022943"],"is_preprint":false},{"year":2021,"finding":"CYP3A4 overexpression in HepG2 cells causes resistance to docetaxel (reduced antiproliferative activity), which is reversed by co-administration of ketoconazole. This resistance is mediated at least partly through impaired activation of caspases 3/7, 8, and 9. CYP3A4 overexpression does not confer resistance to vincristine.","method":"Lentiviral transduction of CYP3A4 into HepG2 cells, MTT proliferation assay, caspase activation assay, ketoconazole inhibition rescue","journal":"Chemico-biological interactions","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional CYP3A4 overexpression with pharmacological rescue by ketoconazole, caspase mechanistic readout, single lab, multiple methods","pmids":["33775687"],"is_preprint":false},{"year":2013,"finding":"CYP3A4 and CYP3A5 are both capable of oxidizing vinorelbine in vitro. CYP3A4+cytochrome b5 and CYP3A5+cytochrome b5 show equivalent Michaelis-Menten constants (Km 2.6 and 3.6 μM respectively) with common Vmax of 1.4 pmol/min/pmol. However, intrinsic clearance in human liver microsomes correlates with CYP3A4 activity, and CYP3A4 produces more of the major metabolite M2 (didehydro-vinorelbine), indicating CYP3A4 as the predominant contributor in vivo.","method":"cDNA-expressed recombinant enzymes, human liver microsomes, selective P450 inhibitors, kinetic analysis, radiolabeled substrate, NMR and mass spectrometry metabolite characterization","journal":"Drug metabolism and disposition","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution with kinetics, human liver microsomes, metabolite structural characterization by NMR/MS, multiple orthogonal methods; single lab","pmids":["23780963"],"is_preprint":false}],"current_model":"CYP3A4 is a hepatic and intestinal microsomal monooxygenase that metabolizes ~50% of clinically used drugs and endogenous compounds (including steroids, bile acids, and vitamin D metabolites) via an iron-porphyrin (heme) catalytic mechanism; its transcription is controlled by a network of nuclear receptors (PXR, CAR, GR, VDR, HNF4α, DBP/E4BP4) acting through a proximal promoter and a distal xenobiotic-responsive enhancer module (XREM at −7.2 to −7.8 kb) plus a newly identified distal regulatory region, while post-transcriptional regulation involves direct miRNA targeting of the CYP3A4 3'-UTR; protein activity is modulated by cytochrome b5 and anionic phospholipid-mimetic anions, and loss-of-function alleles (e.g., CYP3A4*20 with absent heme incorporation, CYP3A4*22 with aberrant splicing) or gain-of-function mutations (e.g., I301T causing accelerated vitamin D inactivation) directly alter drug and hormone metabolism in vivo."},"narrative":{"mechanistic_narrative":"CYP3A4 is a heme-dependent microsomal monooxygenase that oxidizes a broad range of drug and endogenous substrates, including steroids such as testosterone, clinical drugs (midazolam, atorvastatin, paclitaxel, irinotecan, quetiapine, vinorelbine), and the antiviral prodrug pradefovir, often as the predominant or sole catalyzing isoform relative to CYP3A5 [PMID:11714865, PMID:20847137, PMID:16940083, PMID:23780963]. Catalysis proceeds through substrate binding, NADPH-dependent reduction of cytochrome P450 reductase, and interflavin/interprotein electron transfer; these steps and overall monooxygenase rate are stimulated by anionic phospholipid-mimetic citrate ions that bind near a site where the N-terminus splits from the protein core [PMID:26066995], while cytochrome b5 can modulate isoform-specific intrinsic clearance [PMID:19022943]. The enzyme metabolizes endogenous vitamin D metabolites, and a gain-of-function substrate-recognition-site mutation (I301T) accelerates 1,25-dihydroxyvitamin D inactivation and causes vitamin D-dependent rickets type 3 [PMID:29461981]. CYP3A4 is also subject to mechanism-based inactivation, forming a metabolic-intermediate complex with verapamil/norverapamil and apoprotein adducts from a raloxifene diquinone methide intermediate [PMID:15689501, PMID:20405834]. Transcription is governed by an interlocking nuclear-receptor network — PXR, CAR, GR, and VDR acting through proximal and distal (XREM, −7.2 to −7.8 kb) elements, with HNF4α binding required to license PXR/CAR activation and a distal regulatory region physically looping to the promoter as a shared CYP3A enhancer [PMID:12514743, PMID:12130689, PMID:10772626, PMID:12815159, PMID:36045613] — and is further tuned by circadian DBP/E4BP4, p53, and post-transcriptional miR-27b targeting of the 3'-UTR [PMID:18004209, PMID:23054612, PMID:19581388]. Functionally important variation includes the splicing-defective CYP3A4*22 allele that lowers hepatic expression and the heme-null, catalytically dead CYP3A4*20 allele that reduces in vivo drug clearance [PMID:20386561, PMID:26488616, PMID:16580902].","teleology":[{"year":2000,"claim":"Established that CYP3A4 induction is driven by ligand-activated nuclear receptors, resolving how xenobiotics and glucocorticoids upregulate the enzyme.","evidence":"Reporter assays with the −1 kb CYP3A4 promoter and separate/combined GR and PXR transfection in HepG2 cells","pmids":["10772626"],"confidence":"Medium","gaps":["Did not localize the GR/PXR response elements within the promoter","Receptor cooperativity in vivo not addressed"]},{"year":2001,"claim":"Defined how coding variants alter catalytic competence, linking specific residues to turnover and heme incorporation.","evidence":"Site-directed mutagenesis with bacterial heterologous expression and steroid/midazolam/chlorpyrifos activity assays","pmids":["11714865","11470997"],"confidence":"High","gaps":["Allele frequencies and in vivo clinical impact not established","Structural basis of altered kinetics not resolved"]},{"year":2002,"claim":"Mapped CAR response elements in the CYP3A4 5'-flanking region and showed CAR/PXR share these motifs, revealing cooperative receptor regulation.","evidence":"Reporter assays and binding-motif identification at −7720 and −150, with in vivo confirmation","pmids":["12130689"],"confidence":"High","gaps":["Quantitative contribution of each motif to inducibility not resolved","Cofactor requirements not addressed here"]},{"year":2003,"claim":"Identified HNF4α as a required gatekeeper licensing PXR/CAR-mediated activation, and defined the distal (>−3.2 kb / XREM) region needed for constitutive and inducible expression.","evidence":"Reporter assays, EMSA, Hnf4α conditional knockout mice, and CYP3A4/lacZ transgenic mice with deletion analysis","pmids":["12514743","12815159"],"confidence":"High","gaps":["Mechanism by which HNF4α permits receptor action not detailed","Chromatin architecture of the XREM not resolved at this stage"]},{"year":2005,"claim":"Demonstrated isoform-selective mechanism-based inhibition, showing verapamil metabolites trap CYP3A4 (but not CYP3A5) as a metabolic-intermediate complex.","evidence":"Dual-beam spectrophotometry detecting the 455 nm MIC and time-dependent inactivation kinetics with recombinant CYP3A4/CYP3A5 and liver microsomes","pmids":["15689501"],"confidence":"High","gaps":["Structural basis of CYP3A4 vs CYP3A5 selectivity not resolved","In vivo drug-interaction magnitude not quantified"]},{"year":2006,"claim":"Connected a null allele to clinical phenotype and confirmed CYP3A4 as a bioactivating enzyme for a prodrug.","evidence":"CYP3A4*20 expression in yeast/HEK293 showing no heme incorporation plus in vivo midazolam pharmacokinetics; CYP isoform panel and antibody inhibition for pradefovir activation","pmids":["16580902","16940083"],"confidence":"Medium","gaps":["*20 carrier numbers very small","Determinants of heme incorporation failure not defined"]},{"year":2007,"claim":"Revealed circadian control of CYP3A4, explaining ~24 h oscillation in drug-metabolizing capacity.","evidence":"Reporter assays, EMSA confirming DBP binding near the TSS, and E4BP4 repression in serum-shocked HepG2 cells","pmids":["18004209"],"confidence":"Medium","gaps":["In vivo rhythmicity of human CYP3A4 not directly demonstrated here","Integration with nuclear-receptor inputs unresolved"]},{"year":2009,"claim":"Added a post-transcriptional layer, showing miR-27b directly and indirectly (via VDR) suppresses CYP3A4.","evidence":"Luciferase 3'-UTR reporters with MRE mutagenesis, immunoblot, qPCR, and miR-27b overexpression","pmids":["19581388"],"confidence":"Medium","gaps":["Physiological miR-27b levels required for regulation not defined","Single-lab reporter-based mechanism without in vivo confirmation"]},{"year":2010,"claim":"Established CYP3A4*22 as an expression-reducing regulatory allele acting through aberrant splicing, and quantified substrate-dependent effects of other coding alleles.","evidence":"Allelic expression in human liver, minigene transfection, clinical pharmacokinetics, plus Sf21 recombinant kinetics for *16 and *18 across seven substrates","pmids":["20386561","20847137"],"confidence":"High","gaps":["Splice mechanism tissue-specificity not yet shown at this stage","Generalizability of substrate-dependent effects across all substrates unclear"]},{"year":2010,"claim":"Resolved the chemical mechanism of raloxifene-mediated inactivation, distinguishing dehydrogenation from oxygenation.","evidence":"18O-incorporation tracing and mass spectrometry in reconstituted CYP3A4","pmids":["20405834"],"confidence":"High","gaps":["Identity of the modified apoprotein carboxylate residue not defined","Quantitative contribution to clinical inactivation not assessed"]},{"year":2012,"claim":"Expanded the regulatory network to stress and intestinal/seasonal signals, implicating p53 and VDR in CYP3A4 expression.","evidence":"ChIP and reporter assays for p53 binding in hepatocytes; VDR genotyping with intestinal biopsy expression and midazolam pharmacokinetics","pmids":["23054612","22484315"],"confidence":"Medium","gaps":["Physiological relevance of chemotherapy-induced p53 effect uncertain","Causality of VDR genotype-expression association not proven"]},{"year":2015,"claim":"Provided a structural and mechanistic account of allosteric stimulation by anionic effectors, mapping rate-limiting electron-transfer steps.","evidence":"X-ray co-crystallization of CYP3A4 with progesterone and citrate plus functional reconstitution of soluble CYP3A4/CPR","pmids":["26066995"],"confidence":"High","gaps":["Physiological identity of the in vivo anionic activator not established","Quantitative contribution to hepatic activity unknown"]},{"year":2018,"claim":"Demonstrated a gain-of-function disease mechanism, linking an SRS-4 mutation to accelerated vitamin D inactivation and Mendelian rickets.","evidence":"Whole exome sequencing and in vitro activity comparison of I301T mutant vs wild-type toward vitamin D metabolites","pmids":["29461981"],"confidence":"High","gaps":["Structural mechanism described from modeling, not solved structure","Single-case basis for the disease association"]},{"year":2022,"claim":"Established physical promoter-enhancer looping at a distal regulatory region shared across the CYP3A locus and tied DRR SNPs to expression.","evidence":"4C chromatin conformation capture, CRISPR deletion, reporter assays, and human liver cohort (n=246)","pmids":["36045613"],"confidence":"High","gaps":["Trans-factors binding the DRR not identified","Mechanism connecting DRR to nuclear-receptor inputs unresolved"]},{"year":2022,"claim":"Refined the mechanism of small-molecule modulation of PXR-driven CYP3A4 induction via chaperone exchange and coactivator interactions.","evidence":"Co-IP of PXR with HSP90α and RXRα, immunofluorescence for nuclear translocation, qPCR/western with hCAR siRNA","pmids":["35417848"],"confidence":"Medium","gaps":["Single-lab co-IP without orthogonal interaction validation","Generalization beyond the tested ligand unclear"]},{"year":null,"claim":"How the multiple regulatory inputs (HNF4α, PXR/CAR, GR, VDR, p53, circadian DBP/E4BP4, miRNAs, and the distal regulatory region) are integrated at chromatin to set CYP3A4 expression in a given hepatocyte remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking enhancer looping to specific trans-factor occupancy","Quantitative hierarchy among regulatory inputs unknown","In vivo human dynamics of post-transcriptional vs transcriptional control undefined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016491","term_label":"oxidoreductase activity","supporting_discovery_ids":[4,7,14,24]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[15,18]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[14,22]}],"pathway":[{"term_id":"R-HSA-9748784","term_label":"Drug ADME","supporting_discovery_ids":[12,13,18,24]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[4,7]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,20]}],"complexes":[],"partners":["POR","CYB5A","PXR","CAR","HNF4A","VDR","RXRA","HSP90AA1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P08684","full_name":"Cytochrome P450 3A4","aliases":["1,4-cineole 2-exo-monooxygenase","1,8-cineole 2-exo-monooxygenase","Albendazole monooxygenase (sulfoxide-forming)","Albendazole sulfoxidase","CYPIIIA3","CYPIIIA4","Cholesterol 25-hydroxylase","Cytochrome P450 3A3","Cytochrome P450 HLp","Cytochrome P450 NF-25","Cytochrome P450-PCN1","Nifedipine oxidase","Quinine 3-monooxygenase"],"length_aa":503,"mass_kda":57.3,"function":"A cytochrome P450 monooxygenase involved in the metabolism of sterols, steroid hormones, retinoids and fatty acids (PubMed:10681376, PubMed:11093772, PubMed:11555828, PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:19965576, PubMed:20702771, PubMed:21490593, PubMed:21576599). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:12865317, PubMed:14559847, PubMed:15373842, PubMed:15764715, PubMed:21490593, PubMed:21576599, PubMed:2732228). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2, as well as D-ring hydroxylated E1 and E2 at the C-16 position (PubMed:11555828, PubMed:12865317, PubMed:14559847). Plays a role in the metabolism of androgens, particularly in oxidative deactivation of testosterone (PubMed:15373842, PubMed:15764715, PubMed:22773874, PubMed:2732228). Metabolizes testosterone to less biologically active 2beta- and 6beta-hydroxytestosterones (PubMed:15373842, PubMed:15764715, PubMed:2732228). Contributes to the formation of hydroxycholesterols (oxysterols), particularly A-ring hydroxylated cholesterol at the C-4beta position, and side chain hydroxylated cholesterol at the C-25 position, likely contributing to cholesterol degradation and bile acid biosynthesis (PubMed:21576599). Catalyzes bisallylic hydroxylation of polyunsaturated fatty acids (PUFA) (PubMed:9435160). Catalyzes the epoxidation of double bonds of PUFA with a preference for the last double bond (PubMed:19965576). Metabolizes endocannabinoid arachidonoylethanolamide (anandamide) to 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid ethanolamides (EpETrE-EAs), potentially modulating endocannabinoid system signaling (PubMed:20702771). Plays a role in the metabolism of retinoids. Displays high catalytic activity for oxidation of all-trans-retinol to all-trans-retinal, a rate-limiting step for the biosynthesis of all-trans-retinoic acid (atRA) (PubMed:10681376). Further metabolizes atRA toward 4-hydroxyretinoate and may play a role in hepatic atRA clearance (PubMed:11093772). Responsible for oxidative metabolism of xenobiotics. Acts as a 2-exo-monooxygenase for plant lipid 1,8-cineole (eucalyptol) (PubMed:11159812). Metabolizes the majority of the administered drugs. Catalyzes sulfoxidation of the anthelmintics albendazole and fenbendazole (PubMed:10759686). Hydroxylates antimalarial drug quinine (PubMed:8968357). Acts as a 1,4-cineole 2-exo-monooxygenase (PubMed:11695850). Also involved in vitamin D catabolism and calcium homeostasis. Catalyzes the inactivation of the active hormone calcitriol (1-alpha,25-dihydroxyvitamin D(3)) (PubMed:29461981)","subcellular_location":"Endoplasmic reticulum membrane; Microsome membrane","url":"https://www.uniprot.org/uniprotkb/P08684/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CYP3A4","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CYP3A4","total_profiled":1310},"omim":[{"mim_id":"619073","title":"VITAMIN D-DEPENDENT RICKETS, TYPE 3; VDDR3","url":"https://www.omim.org/entry/619073"},{"mim_id":"618018","title":"DRUG METABOLISM, ALTERED, CYP2C8-RELATED","url":"https://www.omim.org/entry/618018"},{"mim_id":"615507","title":"NISCHARIN; NISCH","url":"https://www.omim.org/entry/615507"},{"mim_id":"614546","title":"EFAVIRENZ, POOR METABOLISM OF","url":"https://www.omim.org/entry/614546"},{"mim_id":"609535","title":"DRUG METABOLISM, ALTERED, CYP2C19-RELATED","url":"https://www.omim.org/entry/609535"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Vesicles","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"liver","ntpm":3367.1}],"url":"https://www.proteinatlas.org/search/CYP3A4"},"hgnc":{"alias_symbol":[],"prev_symbol":["CYP3A3"]},"alphafold":{"accession":"P08684","domains":[{"cath_id":"1.10.630.10","chopping":"29-494","consensus_level":"medium","plddt":94.0017,"start":29,"end":494}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P08684","model_url":"https://alphafold.ebi.ac.uk/files/AF-P08684-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P08684-F1-predicted_aligned_error_v6.png","plddt_mean":92.38},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CYP3A4","jax_strain_url":"https://www.jax.org/strain/search?query=CYP3A4"},"sequence":{"accession":"P08684","fasta_url":"https://rest.uniprot.org/uniprotkb/P08684.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P08684/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P08684"}},"corpus_meta":[{"pmid":"20386561","id":"PMC_20386561","title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs.","date":"2010","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/20386561","citation_count":405,"is_preprint":false},{"pmid":"12514743","id":"PMC_12514743","title":"The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4.","date":"2003","source":"Nature medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12514743","citation_count":372,"is_preprint":false},{"pmid":"12065767","id":"PMC_12065767","title":"Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12065767","citation_count":366,"is_preprint":false},{"pmid":"11714865","id":"PMC_11714865","title":"Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos.","date":"2001","source":"The Journal of pharmacology and experimental therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11714865","citation_count":273,"is_preprint":false},{"pmid":"12573484","id":"PMC_12573484","title":"The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors.","date":"2003","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/12573484","citation_count":267,"is_preprint":false},{"pmid":"19581388","id":"PMC_19581388","title":"MicroRNAs regulate CYP3A4 expression via direct and indirect targeting.","date":"2009","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19581388","citation_count":214,"is_preprint":false},{"pmid":"24926778","id":"PMC_24926778","title":"Functional gene variants of CYP3A4.","date":"2014","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/24926778","citation_count":203,"is_preprint":false},{"pmid":"11470997","id":"PMC_11470997","title":"Identification and functional characterization of eight CYP3A4 protein variants.","date":"2001","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11470997","citation_count":191,"is_preprint":false},{"pmid":"12130689","id":"PMC_12130689","title":"Transcriptional regulation of the human CYP3A4 gene by the constitutive androstane receptor.","date":"2002","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12130689","citation_count":188,"is_preprint":false},{"pmid":"12695340","id":"PMC_12695340","title":"Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.","date":"2003","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/12695340","citation_count":183,"is_preprint":false},{"pmid":"16442130","id":"PMC_16442130","title":"MDR- and CYP3A4-mediated drug-herbal interactions.","date":"2006","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/16442130","citation_count":177,"is_preprint":false},{"pmid":"23252948","id":"PMC_23252948","title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.","date":"2013","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/23252948","citation_count":173,"is_preprint":false},{"pmid":"26180597","id":"PMC_26180597","title":"Interactions between CYP3A4 and Dietary Polyphenols.","date":"2015","source":"Oxidative medicine and cellular longevity","url":"https://pubmed.ncbi.nlm.nih.gov/26180597","citation_count":135,"is_preprint":false},{"pmid":"9070608","id":"PMC_9070608","title":"Expression and localization of CYP3A4 and CYP3A5 in human lung.","date":"1997","source":"American journal of respiratory cell and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9070608","citation_count":133,"is_preprint":false},{"pmid":"18040809","id":"PMC_18040809","title":"MDR- and CYP3A4-mediated drug-drug interactions.","date":"2006","source":"Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/18040809","citation_count":132,"is_preprint":false},{"pmid":"15578943","id":"PMC_15578943","title":"CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development.","date":"2004","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/15578943","citation_count":127,"is_preprint":false},{"pmid":"17305497","id":"PMC_17305497","title":"Transcriptional regulation and expression of CYP3A4 in hepatocytes.","date":"2007","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/17305497","citation_count":122,"is_preprint":false},{"pmid":"28012672","id":"PMC_28012672","title":"Effects of triazole fungicides on androgenic disruption and CYP3A4 enzyme activity.","date":"2016","source":"Environmental pollution (Barking, Essex : 1987)","url":"https://pubmed.ncbi.nlm.nih.gov/28012672","citation_count":120,"is_preprint":false},{"pmid":"15548719","id":"PMC_15548719","title":"CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.","date":"2004","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/15548719","citation_count":111,"is_preprint":false},{"pmid":"11907494","id":"PMC_11907494","title":"CYP3A4 variant alleles in white individuals with low CYP3A4 enzyme activity.","date":"2002","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/11907494","citation_count":107,"is_preprint":false},{"pmid":"16580902","id":"PMC_16580902","title":"Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity.","date":"2006","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/16580902","citation_count":96,"is_preprint":false},{"pmid":"22985909","id":"PMC_22985909","title":"Interplay between vitamin D and the drug metabolizing enzyme CYP3A4.","date":"2012","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/22985909","citation_count":94,"is_preprint":false},{"pmid":"14504207","id":"PMC_14504207","title":"CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer.","date":"2003","source":"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology","url":"https://pubmed.ncbi.nlm.nih.gov/14504207","citation_count":94,"is_preprint":false},{"pmid":"26488616","id":"PMC_26488616","title":"CYP3A4 intronic SNP rs35599367 (CYP3A4*22) alters RNA splicing.","date":"2016","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/26488616","citation_count":88,"is_preprint":false},{"pmid":"29461981","id":"PMC_29461981","title":"CYP3A4 mutation causes vitamin D-dependent rickets type 3.","date":"2018","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/29461981","citation_count":85,"is_preprint":false},{"pmid":"8877031","id":"PMC_8877031","title":"Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.","date":"1996","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/8877031","citation_count":84,"is_preprint":false},{"pmid":"17975661","id":"PMC_17975661","title":"Gut instincts: CYP3A4 and intestinal drug metabolism.","date":"2007","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/17975661","citation_count":81,"is_preprint":false},{"pmid":"21920351","id":"PMC_21920351","title":"Metformin suppresses pregnane X receptor (PXR)-regulated transactivation of CYP3A4 gene.","date":"2011","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21920351","citation_count":79,"is_preprint":false},{"pmid":"18004209","id":"PMC_18004209","title":"Molecular basis for rhythmic expression of CYP3A4 in serum-shocked HepG2 cells.","date":"2007","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/18004209","citation_count":73,"is_preprint":false},{"pmid":"25332983","id":"PMC_25332983","title":"The role of CYP3A4 in the biotransformation of bile acids and therapeutic implication for cholestasis.","date":"2014","source":"Annals of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25332983","citation_count":72,"is_preprint":false},{"pmid":"15581591","id":"PMC_15581591","title":"Modelling atypical CYP3A4 kinetics: principles and pragmatism.","date":"2005","source":"Archives of biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/15581591","citation_count":69,"is_preprint":false},{"pmid":"18805405","id":"PMC_18805405","title":"PXR-mediated transcriptional activation of CYP3A4 by cryptotanshinone and tanshinone IIA.","date":"2008","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/18805405","citation_count":67,"is_preprint":false},{"pmid":"28558634","id":"PMC_28558634","title":"Differential Regulation of CYP3A4 and CYP3A5 and its Implication in Drug Discovery.","date":"2017","source":"Current drug metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/28558634","citation_count":66,"is_preprint":false},{"pmid":"10772626","id":"PMC_10772626","title":"Regulation of the CYP3A4 gene by hydrocortisone and xenobiotics: role of the glucocorticoid and pregnane X receptors.","date":"2000","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/10772626","citation_count":62,"is_preprint":false},{"pmid":"15689501","id":"PMC_15689501","title":"Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil.","date":"2005","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/15689501","citation_count":61,"is_preprint":false},{"pmid":"22906825","id":"PMC_22906825","title":"DNA methylation dynamics in the hepatic CYP3A4 gene promoter.","date":"2012","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/22906825","citation_count":60,"is_preprint":false},{"pmid":"34306041","id":"PMC_34306041","title":"CYP3A4 Genotyping in Clinical Practice: Ready for Implementation?","date":"2021","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34306041","citation_count":58,"is_preprint":false},{"pmid":"17083953","id":"PMC_17083953","title":"Hyperforin and its analogues inhibit CYP3A4 enzyme activity.","date":"2006","source":"Phytochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17083953","citation_count":55,"is_preprint":false},{"pmid":"12815159","id":"PMC_12815159","title":"Transgenic mouse models of human CYP3A4 gene regulation.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12815159","citation_count":55,"is_preprint":false},{"pmid":"19022943","id":"PMC_19022943","title":"Metabolism of quetiapine by CYP3A4 and CYP3A5 in presence or absence of cytochrome B5.","date":"2008","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19022943","citation_count":54,"is_preprint":false},{"pmid":"10634135","id":"PMC_10634135","title":"Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.","date":"1999","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/10634135","citation_count":52,"is_preprint":false},{"pmid":"23054612","id":"PMC_23054612","title":"Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53.","date":"2012","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/23054612","citation_count":52,"is_preprint":false},{"pmid":"21447389","id":"PMC_21447389","title":"Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans.","date":"2011","source":"European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21447389","citation_count":51,"is_preprint":false},{"pmid":"19910514","id":"PMC_19910514","title":"Genetic variants of CYP3A4 and CYP3A5 in cynomolgus and rhesus macaques.","date":"2009","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/19910514","citation_count":51,"is_preprint":false},{"pmid":"23876595","id":"PMC_23876595","title":"Effect of Chinese herbs on CYP3A4 activity and expression in vitro.","date":"2013","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/23876595","citation_count":49,"is_preprint":false},{"pmid":"21750469","id":"PMC_21750469","title":"Genetic epidemiology of induced CYP3A4 activity.","date":"2011","source":"Pharmacogenetics and genomics","url":"https://pubmed.ncbi.nlm.nih.gov/21750469","citation_count":49,"is_preprint":false},{"pmid":"28951593","id":"PMC_28951593","title":"MicroRNA regulation of CYP 1A2, CYP3A4 and CYP2E1 expression in acetaminophen toxicity.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28951593","citation_count":48,"is_preprint":false},{"pmid":"22484315","id":"PMC_22484315","title":"Intestinal CYP3A4 and midazolam disposition in vivo associate with VDR polymorphisms and show seasonal variation.","date":"2012","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/22484315","citation_count":44,"is_preprint":false},{"pmid":"26066995","id":"PMC_26066995","title":"Anion-Dependent Stimulation of CYP3A4 Monooxygenase.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26066995","citation_count":43,"is_preprint":false},{"pmid":"21091656","id":"PMC_21091656","title":"Pregnane X receptor- and CYP3A4-humanized mouse models and their applications.","date":"2011","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21091656","citation_count":42,"is_preprint":false},{"pmid":"29071751","id":"PMC_29071751","title":"PXR mediated induction of CYP3A4, CYP1A2, and P-gp by Mitragyna speciosa and its alkaloids.","date":"2017","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/29071751","citation_count":42,"is_preprint":false},{"pmid":"19530969","id":"PMC_19530969","title":"Statin regulation of CYP3A4 and CYP3A5 expression.","date":"2009","source":"Pharmacogenomics","url":"https://pubmed.ncbi.nlm.nih.gov/19530969","citation_count":41,"is_preprint":false},{"pmid":"36732076","id":"PMC_36732076","title":"Activation/Inactivation of Anticancer Drugs by CYP3A4: Influencing Factors for Personalized Cancer Therapy.","date":"2023","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/36732076","citation_count":41,"is_preprint":false},{"pmid":"15459178","id":"PMC_15459178","title":"Allelic expression imbalance of the human CYP3A4 gene and individual phenotypic status.","date":"2004","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15459178","citation_count":41,"is_preprint":false},{"pmid":"28849250","id":"PMC_28849250","title":"Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.","date":"2017","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28849250","citation_count":41,"is_preprint":false},{"pmid":"20847137","id":"PMC_20847137","title":"CYP3A4*16 and CYP3A4*18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs.","date":"2010","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/20847137","citation_count":40,"is_preprint":false},{"pmid":"16755466","id":"PMC_16755466","title":"Hypericum perforatum: which constituents may induce intestinal MDR1 and CYP3A4 mRNA expression?","date":"2006","source":"Planta medica","url":"https://pubmed.ncbi.nlm.nih.gov/16755466","citation_count":39,"is_preprint":false},{"pmid":"20361990","id":"PMC_20361990","title":"Endosulfan induces CYP2B6 and CYP3A4 by activating the pregnane X receptor.","date":"2010","source":"Toxicology and applied pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/20361990","citation_count":39,"is_preprint":false},{"pmid":"8946469","id":"PMC_8946469","title":"Selective expression of CYP3A5 and not CYP3A4 in human blood.","date":"1996","source":"Pharmacogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8946469","citation_count":37,"is_preprint":false},{"pmid":"22076448","id":"PMC_22076448","title":"Polycyclic aromatic hydrocarbons activate CYP3A4 gene transcription through human pregnane X receptor.","date":"2011","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/22076448","citation_count":35,"is_preprint":false},{"pmid":"14643022","id":"PMC_14643022","title":"Expression of CYP3A4 in human breast tumour and non-tumour tissues.","date":"2003","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/14643022","citation_count":34,"is_preprint":false},{"pmid":"17936928","id":"PMC_17936928","title":"CYP3A4 and pregnane X receptor humanized mice.","date":"2007","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/17936928","citation_count":31,"is_preprint":false},{"pmid":"21838784","id":"PMC_21838784","title":"CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast.","date":"2012","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/21838784","citation_count":31,"is_preprint":false},{"pmid":"25689036","id":"PMC_25689036","title":"Expression of CYP3A4 and CYP3A7 in Human Foetal Tissues and its Correlation with Nuclear Receptors.","date":"2015","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/25689036","citation_count":30,"is_preprint":false},{"pmid":"25341566","id":"PMC_25341566","title":"Resveratrol suppresses the inducible expression of CYP3A4 through the pregnane X receptor.","date":"2014","source":"Journal of pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25341566","citation_count":30,"is_preprint":false},{"pmid":"33775687","id":"PMC_33775687","title":"Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.","date":"2021","source":"Chemico-biological interactions","url":"https://pubmed.ncbi.nlm.nih.gov/33775687","citation_count":30,"is_preprint":false},{"pmid":"32106230","id":"PMC_32106230","title":"A comparison of hepato-cellular in vitro platforms to study CYP3A4 induction.","date":"2020","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/32106230","citation_count":30,"is_preprint":false},{"pmid":"29117640","id":"PMC_29117640","title":"Functional Characterization of 22 CYP3A4 Protein Variants to Metabolize Ibrutinib In Vitro.","date":"2017","source":"Basic & clinical pharmacology & toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/29117640","citation_count":28,"is_preprint":false},{"pmid":"38540257","id":"PMC_38540257","title":"Flavonoids as CYP3A4 Inhibitors In Vitro.","date":"2024","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/38540257","citation_count":27,"is_preprint":false},{"pmid":"29105855","id":"PMC_29105855","title":"Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro.","date":"2018","source":"British journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29105855","citation_count":27,"is_preprint":false},{"pmid":"34069400","id":"PMC_34069400","title":"Characterization of the CYP3A4 Enzyme Inhibition Potential of Selected Flavonoids.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34069400","citation_count":27,"is_preprint":false},{"pmid":"32931777","id":"PMC_32931777","title":"Pregnancy-Related Hormones Increase Nifedipine Metabolism in Human Hepatocytes by Inducing CYP3A4 Expression.","date":"2020","source":"Journal of pharmaceutical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32931777","citation_count":27,"is_preprint":false},{"pmid":"17825266","id":"PMC_17825266","title":"Regulation of CYP3A4 and CYP2B6 expression by liver X receptor agonists.","date":"2007","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/17825266","citation_count":26,"is_preprint":false},{"pmid":"25684704","id":"PMC_25684704","title":"Investigation of CYP3A4 and CYP2D6 Interactions of Withania somnifera and Centella asiatica in Human Liver Microsomes.","date":"2015","source":"Phytotherapy research : PTR","url":"https://pubmed.ncbi.nlm.nih.gov/25684704","citation_count":26,"is_preprint":false},{"pmid":"30283337","id":"PMC_30283337","title":"The Modulatory Role of CYP3A4 in Dictamnine-Induced Hepatotoxicity.","date":"2018","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/30283337","citation_count":25,"is_preprint":false},{"pmid":"12463723","id":"PMC_12463723","title":"Pioglitazone: effect on CYP3A4 activity.","date":"2002","source":"Journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12463723","citation_count":25,"is_preprint":false},{"pmid":"20503067","id":"PMC_20503067","title":"Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells.","date":"2010","source":"Pharmaceutical research","url":"https://pubmed.ncbi.nlm.nih.gov/20503067","citation_count":24,"is_preprint":false},{"pmid":"17526937","id":"PMC_17526937","title":"Tamoxifen activates CYP3A4 and MDR1 genes through steroid and xenobiotic receptor in breast cancer cells.","date":"2006","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/17526937","citation_count":24,"is_preprint":false},{"pmid":"33262574","id":"PMC_33262574","title":"Functional Measurement of CYP2C9 and CYP3A4 Allelic Polymorphism on Sildenafil Metabolism.","date":"2020","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33262574","citation_count":23,"is_preprint":false},{"pmid":"29283173","id":"PMC_29283173","title":"CYP3A4 inducer and inhibitor strongly affect the pharmacokinetics of triptolide and its derivative in rats.","date":"2017","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/29283173","citation_count":23,"is_preprint":false},{"pmid":"33260381","id":"PMC_33260381","title":"Screening of Human CYP1A2 and CYP3A4 Inhibitors from Seaweed In Silico and In Vitro.","date":"2020","source":"Marine drugs","url":"https://pubmed.ncbi.nlm.nih.gov/33260381","citation_count":22,"is_preprint":false},{"pmid":"23780963","id":"PMC_23780963","title":"The relative contributions of CYP3A4 and CYP3A5 to the metabolism of vinorelbine.","date":"2013","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/23780963","citation_count":22,"is_preprint":false},{"pmid":"20959500","id":"PMC_20959500","title":"Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.","date":"2010","source":"The Annals of pharmacotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/20959500","citation_count":21,"is_preprint":false},{"pmid":"24832206","id":"PMC_24832206","title":"Interactions of endosulfan and methoxychlor involving CYP3A4 and CYP2B6 in human HepaRG cells.","date":"2014","source":"Drug metabolism and disposition: the biological fate of chemicals","url":"https://pubmed.ncbi.nlm.nih.gov/24832206","citation_count":21,"is_preprint":false},{"pmid":"20405834","id":"PMC_20405834","title":"CYP3A4-Mediated oxygenation versus dehydrogenation of raloxifene.","date":"2010","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20405834","citation_count":21,"is_preprint":false},{"pmid":"35417848","id":"PMC_35417848","title":"Panaxytriol upregulates CYP3A4 expression based on the interaction of PXR, CAR, HSP90α, and RXRα.","date":"2022","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/35417848","citation_count":20,"is_preprint":false},{"pmid":"16940083","id":"PMC_16940083","title":"Metabolic activation of pradefovir by CYP3A4 and its potential as an inhibitor or inducer.","date":"2006","source":"Antimicrobial agents and chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/16940083","citation_count":20,"is_preprint":false},{"pmid":"27836570","id":"PMC_27836570","title":"Metabolic-induced cytotoxicity of diosbulbin B in CYP3A4-expressing cells.","date":"2016","source":"Toxicology in vitro : an international journal published in association with BIBRA","url":"https://pubmed.ncbi.nlm.nih.gov/27836570","citation_count":20,"is_preprint":false},{"pmid":"32364081","id":"PMC_32364081","title":"Paclitaxel Nanoparticles Induce Apoptosis and Regulate TXR1, CYP3A4 and CYP2C8 in Breast Cancer and Hepatoma Cells.","date":"2020","source":"Anti-cancer agents in medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32364081","citation_count":20,"is_preprint":false},{"pmid":"32270716","id":"PMC_32270716","title":"Transcriptional regulation of CYP3A4 by nuclear receptors in human hepatocytes under hypoxia.","date":"2020","source":"Drug metabolism reviews","url":"https://pubmed.ncbi.nlm.nih.gov/32270716","citation_count":18,"is_preprint":false},{"pmid":"27261575","id":"PMC_27261575","title":"Drug membrane transporters and CYP3A4 are affected by hypericin, hyperforin or aristoforin in colon adenocarcinoma cells.","date":"2016","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/27261575","citation_count":18,"is_preprint":false},{"pmid":"26089940","id":"PMC_26089940","title":"Comparison of Paeoniflorin and Albiflorin on Human CYP3A4 and CYP2D6.","date":"2015","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/26089940","citation_count":17,"is_preprint":false},{"pmid":"27727071","id":"PMC_27727071","title":"Developmental regulation of CYP3A4 and CYP3A7 in Chinese Han population.","date":"2016","source":"Drug metabolism and pharmacokinetics","url":"https://pubmed.ncbi.nlm.nih.gov/27727071","citation_count":17,"is_preprint":false},{"pmid":"29926893","id":"PMC_29926893","title":"CYP3A4 gene polymorphism is correlated with individual consumption of sufentanil.","date":"2018","source":"Acta anaesthesiologica Scandinavica","url":"https://pubmed.ncbi.nlm.nih.gov/29926893","citation_count":17,"is_preprint":false},{"pmid":"26340669","id":"PMC_26340669","title":"Fluoxetine reduces CES1, CES2, and CYP3A4 expression through decreasing PXR and increasing DEC1 in HepG2 cells.","date":"2015","source":"Xenobiotica; the fate of foreign compounds in biological systems","url":"https://pubmed.ncbi.nlm.nih.gov/26340669","citation_count":17,"is_preprint":false},{"pmid":"30218411","id":"PMC_30218411","title":"Correlations between CYP3A4 polymorphism and susceptibility to breast cancer in Chinese Han population.","date":"2018","source":"International journal of clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/30218411","citation_count":16,"is_preprint":false},{"pmid":"36045613","id":"PMC_36045613","title":"Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5.","date":"2022","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/36045613","citation_count":15,"is_preprint":false},{"pmid":"34474151","id":"PMC_34474151","title":"Cytochrome P450 3A4 (CYP3A4) protein quantification using capillary western blot technology and total protein normalization.","date":"2021","source":"Journal of pharmacological and toxicological methods","url":"https://pubmed.ncbi.nlm.nih.gov/34474151","citation_count":15,"is_preprint":false},{"pmid":"31293154","id":"PMC_31293154","title":"Characterization of Genetic Variation in CYP3A4 on the Metabolism of Cabozantinib in Vitro.","date":"2019","source":"Chemical research in toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/31293154","citation_count":15,"is_preprint":false},{"pmid":"24443221","id":"PMC_24443221","title":"Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.","date":"2014","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/24443221","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54584,"output_tokens":6903,"usd":0.133649,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15863,"output_tokens":4564,"usd":0.096708,"stage2_stop_reason":"end_turn"},"total_usd":0.230357,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"HNF4α is required for PXR- and CAR-mediated transcriptional activation of CYP3A4. A specific cis-acting element in the CYP3A4 gene enhancer confers HNF4α binding, which then permits PXR- and CAR-mediated gene activation. Conditional hepatic deletion of Hnf4α in mice reduced basal and inducible CYP3A expression.\",\n      \"method\": \"Reporter gene assays, electrophoretic mobility shift assay (EMSA), conditional knockout mice (Hnf4α deletion), cell-based transfection\",\n      \"journal\": \"Nature medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal reporter assays, EMSA identifying cis-element, in vivo conditional KO validation; multiple orthogonal methods in a single rigorous study\",\n      \"pmids\": [\"12514743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CAR (constitutive androstane receptor) trans-activates CYP3A4 expression both in vitro and in vivo. CAR responsiveness is mediated by two high-affinity binding motifs at approximately −7720 and −150 bases upstream of the transcription start site. These same CAR response elements also mediate PXR-mediated trans-activation, indicating cooperative interplay between CAR and PXR in CYP3A4 regulation.\",\n      \"method\": \"Reporter gene assays in cell lines, in vivo studies, identification of CAR binding motifs in CYP3A4 5'-flanking region\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro and in vivo evidence, identified specific binding motifs, multiple orthogonal methods\",\n      \"pmids\": [\"12130689\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"An intronic SNP in CYP3A4 (rs35599367, C>T in intron 6; designated CYP3A4*22) causes allelic expression imbalance in human liver. Livers with CC genotype have 1.7-fold higher mRNA and 2.5-fold higher enzyme activity compared to CT/TT carriers, with functional consequences for statin metabolism.\",\n      \"method\": \"Allelic CYP3A4 hnRNA and mRNA expression measurement in 76 human liver samples, minigene transfection in cell culture, pharmacokinetic analysis in 235 patients\",\n      \"journal\": \"The pharmacogenomics journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro minigene assay mechanistically linking SNP to expression, validated in human liver samples and clinical cohort; multiple orthogonal methods\",\n      \"pmids\": [\"20386561\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CYP3A4*22 (rs35599367 C>T in intron 6) reduces mRNA/protein expression by promoting formation of a nonfunctional alternative splice variant with partial intron 6 retention in liver but not in small intestines, demonstrating tissue-specific splicing as the mechanism of reduced expression.\",\n      \"method\": \"Human liver RNA analysis, CYP3A4 minigene transfection in HepG2 (liver) and LS-174T (intestinal) cell lines\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — minigene functional assay with allele comparison, validated in human liver tissue, tissue-specificity confirmed with two cell lines\",\n      \"pmids\": [\"26488616\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CYP3A4 variant F189S exhibits lower turnover numbers for testosterone and chlorpyrifos, while L293P has higher turnover numbers for both substrates, compared to wild-type CYP3A4*1. Variants M445T and P467S showed no significant difference from wild-type in catalytic activity.\",\n      \"method\": \"Site-directed mutagenesis of cDNA, heterologous expression in E. coli, in vitro enzyme activity assay with testosterone and chlorpyrifos as substrates\",\n      \"journal\": \"The Journal of pharmacology and experimental therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with mutagenesis, multiple substrates tested, single lab\",\n      \"pmids\": [\"11714865\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Two CYP3A4 protein variants (R130Q and P416L) fail to produce detectable P450 holoprotein when expressed in bacteria. T363M is expressed at significantly lower levels than wild-type. L373F displays a significantly altered testosterone metabolite profile and a four-fold increase in Km for 1'-OH midazolam formation.\",\n      \"method\": \"Heterologous bacterial expression system, steroid hydroxylase activity assays, midazolam hydroxylation kinetics\",\n      \"journal\": \"Pharmacogenetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with multiple alleles characterized by activity assays, single lab\",\n      \"pmids\": [\"11470997\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CYP3A4*20 contains a premature stop codon yielding a truncated protein that does not incorporate heme and is completely devoid of catalytic activity. The heterozygous carrier showed low systemic midazolam clearance in vivo, confirming genotype-phenotype correlation.\",\n      \"method\": \"DNA sequencing, heterologous expression in yeast and HEK293 cells, in vivo midazolam pharmacokinetics (phenotyping)\",\n      \"journal\": \"Clinical pharmacology and therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Moderate — heterologous expression demonstrating absent heme incorporation and zero catalytic activity, confirmed with in vivo pharmacokinetics\",\n      \"pmids\": [\"16580902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"A de novo missense mutation c.902T>C (p.I301T) in CYP3A4 alters substrate recognition site 4 (SRS-4) conformation. The mutant CYP3A4 oxidizes 1,25-dihydroxyvitamin D with 10-fold greater activity than wild-type CYP3A4, and 2-fold greater activity than CYP24A1, causing accelerated vitamin D inactivation and vitamin D-dependent rickets type 3.\",\n      \"method\": \"Whole exome sequencing, in vitro enzyme activity assay comparing mutant vs wild-type CYP3A4 activity toward vitamin D metabolites\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution showing 10-fold gain-of-function toward vitamin D metabolites, mutant structurally characterized at SRS-4, linked to clinical phenotype\",\n      \"pmids\": [\"29461981\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"miR-27b directly targets the 3'-UTR of CYP3A4 and suppresses its protein expression by >30%. miR-27b also indirectly regulates CYP3A4 transcription by targeting the VDR 3'-UTR, reducing VDR levels. Disruption of the miRNA response element (MRE) within CYP3A4 3'UTR led to 2- to 3-fold increase in reporter activity.\",\n      \"method\": \"Luciferase reporter assays with CYP3A4 3'UTR, site-directed mutagenesis of MRE, immunoblot analysis, qPCR, overexpression of miR-27b in cell lines\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase reporter with MRE disruption plus immunoblot protein quantification, single lab, two orthogonal methods\",\n      \"pmids\": [\"19581388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The circadian transcription factor DBP activates CYP3A4 transcription by binding to a DNA sequence near the transcription start site, driving rhythmic (~24 h) oscillation in CYP3A4 mRNA and metabolic activity. The negative circadian clock component E4BP4 represses DBP-mediated CYP3A4 transcription.\",\n      \"method\": \"Luciferase reporter gene analysis, electrophoretic mobility shift assay (EMSA), serum-shocked HepG2 cells as circadian model\",\n      \"journal\": \"Pharmacogenetics and genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA confirmed direct DBP binding to CYP3A4 promoter element, reporter assays demonstrated E4BP4 repression, single lab\",\n      \"pmids\": [\"18004209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Both the glucocorticoid receptor (GR) and pregnane X receptor (PXR) mediate hydrocortisone-dependent induction of CYP3A4 via the −1 kb promoter region. PXR decreases the EC50 for hydrocortisone-dependent induction by 3.3-fold. Rifampicin-dependent activation favors PXR over GR.\",\n      \"method\": \"Reporter gene system with −1 kb CYP3A4 promoter in HepG2 cells, separate and combined transfection of hGR and hPXR expression plasmids\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-based reporter assay with receptor-specific transfection, dose-response analysis, single lab\",\n      \"pmids\": [\"10772626\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Transgenic mice carrying the human CYP3A4 upstream regulatory region linked to lacZ show that sequences beyond −3.2 kb are required for both constitutive expression and xenobiotic induction. PXR/CAR-activating reagents (dexamethasone, pregnenolone 16α-carbonitrile, phenobarbital) induce expression through the xenobiotic-responsive enhancer module (XREM, −7.2 to −7.8 kb). Induction operates primarily through zonal recruitment of more hepatocytes to expression.\",\n      \"method\": \"CYP3A4/lacZ transgenic mice, histochemical staining for β-galactosidase, deletion construct analysis\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo transgenic mouse model, deletion analysis defining required regulatory region, single lab\",\n      \"pmids\": [\"12815159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Verapamil and its metabolite N-desalkylverapamil (D617) form a metabolic-intermediate complex (MIC) with CYP3A4 (characteristic 455 nm peak) but not with CYP3A5, demonstrating differential mechanism-based inhibition. Norverapamil inactivates CYP3A4 with kinact = 0.30 min−1 and KI = 10.3 μM, but inactivates CYP3A5 ~45-fold less efficiently.\",\n      \"method\": \"Dual beam spectrophotometry for MIC detection, time-dependent inhibition assays with cDNA-expressed CYP3A4 and CYP3A5, human liver microsomes\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct spectrophotometric detection of MIC, quantitative kinetics with recombinant enzymes and human liver microsomes, multiple orthogonal methods\",\n      \"pmids\": [\"15689501\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CYP3A4*16 (T185S, found in East Asians) exhibits considerably reduced intrinsic clearance (by 60–84%) for midazolam, carbamazepine, atorvastatin, paclitaxel, and irinotecan due to increased Km values, while CYP3A4*18 (L293P) shows reduced Vmax for midazolam, paclitaxel, docetaxel, and irinotecan with unchanged Km values. Both alleles show substrate-dependent effects.\",\n      \"method\": \"Heterologous expression in Sf21 insect cell microsomes with human NADPH-P450 reductase, kinetic assays with seven substrates\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with recombinant enzymes, kinetic parameters (Km, Vmax) for multiple substrates, single lab\",\n      \"pmids\": [\"20847137\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Citrate ions, which mimic anionic phospholipids of the microsomal membrane, bind CYP3A4 at a site near the N-terminus where it splits from the protein core, and stimulate CYP3A4 monooxygenase activity in a concentration-dependent manner. CYP3A4-substrate binding, NADPH-dependent reduction of CPR, and interflavin and interprotein electron transfer were identified as citrate-sensitive steps.\",\n      \"method\": \"X-ray co-crystallization of CYP3A4 with progesterone and citrate, functional assays of soluble CYP3A4/CPR reconstituted system, comparative analysis of anions\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — crystal structure identifying citrate-binding site plus functional reconstitution assay identifying mechanistic steps, single rigorous study\",\n      \"pmids\": [\"26066995\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Raloxifene undergoes CYP3A4-mediated dehydrogenation to a reactive diquinone methide intermediate (not via arene oxide), which forms adducts with a carboxylic acid moiety of CYP3A4 apoprotein, causing mechanism-based inactivation. 7-Hydroxyraloxifene is produced by hydrolysis from the putative ester conjugate rather than direct oxygenation.\",\n      \"method\": \"18O-incorporation studies with isotopically labeled substrates in reconstituted CYP3A4 system, mass spectrometry metabolite analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — 18O-isotope tracing with reconstituted enzyme, mechanistically distinguishes oxygenation vs dehydrogenation pathway, single rigorous study\",\n      \"pmids\": [\"20405834\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"p53 directly binds p53-responsive elements in CYP3A4 regulatory DNA and enhances CYP3A4 transcription. Activation of p53 by chemotherapeutic agents (cisplatin, etoposide, doxorubicin) induces CYP3A4 expression and enzymatic activity in a p53-dependent manner in human hepatocytes.\",\n      \"method\": \"Microarray screen, chromatin immunoprecipitation (ChIP) for p53 binding to CYP3A4 regulatory regions, reporter gene assays, qPCR, enzymatic activity assays in HepG2, Huh6, and primary human hepatocytes\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP demonstrating direct p53 binding to CYP3A4 gene regulatory region, reporter gene assay, functional activity assay; single lab, multiple methods\",\n      \"pmids\": [\"23054612\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Metformin suppresses PXR-mediated CYP3A4 expression in human hepatocytes by disrupting PXR's interaction with steroid receptor coactivator-1 (SRC1), independently of the PXR ligand binding pocket. Metformin also inhibited VDR-, GR-, and CAR-mediated induction of CYP3A4. AMPK activation and SHP upregulation were not involved in this mechanism.\",\n      \"method\": \"Reporter gene assays, qRT-PCR in human hepatocytes, two-hybrid assay (PXR-SRC1 interaction), Pxr−/− mouse experiments\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — two-hybrid assay identifying disruption of PXR-SRC1 interaction as mechanism, in vivo Pxr−/− mouse validation, single lab, multiple methods\",\n      \"pmids\": [\"21920351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CYP3A4 catalyzes the metabolic activation of pradefovir to its active antiviral form PMEA. This conversion is inhibited by ketoconazole and a monoclonal antibody specific to CYP3A4. In human liver microsomes, Km = 60 μM and Vmax = 228 pmol/min/mg protein. No other cDNA-expressed CYP isoform catalyzed this conversion.\",\n      \"method\": \"cDNA-expressed CYP isoforms panel, human liver microsomes with kinetic parameters, CYP3A4-specific inhibitors (ketoconazole and monoclonal antibody 3A4)\",\n      \"journal\": \"Antimicrobial agents and chemotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with CYP isoform panel and kinetics, antibody-based inhibition confirming CYP3A4 specificity, single lab\",\n      \"pmids\": [\"16940083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VDR polymorphisms (BsmIG>A, Cdx2-3731G>A, GATA-1012A>G) are significantly associated with intestinal CYP3A4 expression and activity. Intestinal CYP3A4 expression shows seasonal variation, being significantly higher between April and September, likely related to annual changes in UV sunlight and vitamin D levels activating VDR-mediated transcription.\",\n      \"method\": \"Genotyping of VDR polymorphisms, CYP3A4 protein/mRNA measurement in intestinal biopsies, midazolam pharmacokinetics in patients\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct measurement of CYP3A4 expression linked to VDR genotype and seasonal variation, correlation with midazolam pharmacokinetics; single lab\",\n      \"pmids\": [\"22484315\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A distal regulatory region (DRR) physically interacts with the CYP3A4 promoter (detected by 4C chromatin conformation capture). CRISPR-mediated deletion of the DRR decreased expression of CYP3A4, CYP3A5, and CYP3A7, identifying it as a shared enhancer. Two SNPs (rs115025140 and rs776744/rs776742) within the DRR increase enhancer-driven transcription in reporter assays and are associated with increased CYP3A4/CYP3A5 expression in human liver.\",\n      \"method\": \"4C chromatin conformation capture, CRISPR deletion, luciferase reporter assays, CYP3A4 mRNA and protein measurement in human liver cohort (n=246)\",\n      \"journal\": \"Clinical and translational science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — 4C assay identifying physical promoter-enhancer interaction, CRISPR functional deletion, reporter assays, human liver cohort validation; multiple orthogonal methods\",\n      \"pmids\": [\"36045613\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Panaxytriol upregulates CYP3A4 expression by promoting PXR dissociation from HSP90α and enhancing PXR binding to RXRα, facilitating PXR nuclear translocation and transcriptional activation. At high concentrations, CAR undergoes a similar mechanism but generally antagonizes PXR binding to RXRα.\",\n      \"method\": \"Co-immunoprecipitation (PXR/CAR binding to RXRα and HSP90α), immunofluorescence for nuclear translocation, qPCR, western blot, siRNA silencing of hCAR\",\n      \"journal\": \"Phytomedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — co-IP demonstrating altered PXR-HSP90α and PXR-RXRα interactions, nuclear translocation confirmed, single lab, multiple methods\",\n      \"pmids\": [\"35417848\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Quetiapine is metabolized by CYP3A4 with substantially higher intrinsic clearance than by CYP3A5 (<35% relative activity). CYP3A5 produces a different metabolic pattern, with O-desalkylquetiapine constituting a higher proportion of metabolites. Coexpressed cytochrome b5 decreases CYP3A4 intrinsic clearance for quetiapine 3-fold but has no effect on CYP3A5 clearance.\",\n      \"method\": \"In vitro metabolism assays with CYP3A4 and CYP3A5 insect cell microsomes ± cytochrome b5, substrate depletion kinetics, metabolite identification\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution comparing recombinant CYP3A4 vs CYP3A5 with kinetics, cytochrome b5 effect characterized, single lab\",\n      \"pmids\": [\"19022943\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CYP3A4 overexpression in HepG2 cells causes resistance to docetaxel (reduced antiproliferative activity), which is reversed by co-administration of ketoconazole. This resistance is mediated at least partly through impaired activation of caspases 3/7, 8, and 9. CYP3A4 overexpression does not confer resistance to vincristine.\",\n      \"method\": \"Lentiviral transduction of CYP3A4 into HepG2 cells, MTT proliferation assay, caspase activation assay, ketoconazole inhibition rescue\",\n      \"journal\": \"Chemico-biological interactions\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional CYP3A4 overexpression with pharmacological rescue by ketoconazole, caspase mechanistic readout, single lab, multiple methods\",\n      \"pmids\": [\"33775687\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CYP3A4 and CYP3A5 are both capable of oxidizing vinorelbine in vitro. CYP3A4+cytochrome b5 and CYP3A5+cytochrome b5 show equivalent Michaelis-Menten constants (Km 2.6 and 3.6 μM respectively) with common Vmax of 1.4 pmol/min/pmol. However, intrinsic clearance in human liver microsomes correlates with CYP3A4 activity, and CYP3A4 produces more of the major metabolite M2 (didehydro-vinorelbine), indicating CYP3A4 as the predominant contributor in vivo.\",\n      \"method\": \"cDNA-expressed recombinant enzymes, human liver microsomes, selective P450 inhibitors, kinetic analysis, radiolabeled substrate, NMR and mass spectrometry metabolite characterization\",\n      \"journal\": \"Drug metabolism and disposition\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution with kinetics, human liver microsomes, metabolite structural characterization by NMR/MS, multiple orthogonal methods; single lab\",\n      \"pmids\": [\"23780963\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CYP3A4 is a hepatic and intestinal microsomal monooxygenase that metabolizes ~50% of clinically used drugs and endogenous compounds (including steroids, bile acids, and vitamin D metabolites) via an iron-porphyrin (heme) catalytic mechanism; its transcription is controlled by a network of nuclear receptors (PXR, CAR, GR, VDR, HNF4α, DBP/E4BP4) acting through a proximal promoter and a distal xenobiotic-responsive enhancer module (XREM at −7.2 to −7.8 kb) plus a newly identified distal regulatory region, while post-transcriptional regulation involves direct miRNA targeting of the CYP3A4 3'-UTR; protein activity is modulated by cytochrome b5 and anionic phospholipid-mimetic anions, and loss-of-function alleles (e.g., CYP3A4*20 with absent heme incorporation, CYP3A4*22 with aberrant splicing) or gain-of-function mutations (e.g., I301T causing accelerated vitamin D inactivation) directly alter drug and hormone metabolism in vivo.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CYP3A4 is a heme-dependent microsomal monooxygenase that oxidizes a broad range of drug and endogenous substrates, including steroids such as testosterone, clinical drugs (midazolam, atorvastatin, paclitaxel, irinotecan, quetiapine, vinorelbine), and the antiviral prodrug pradefovir, often as the predominant or sole catalyzing isoform relative to CYP3A5 [#4, #13, #18, #24]. Catalysis proceeds through substrate binding, NADPH-dependent reduction of cytochrome P450 reductase, and interflavin/interprotein electron transfer; these steps and overall monooxygenase rate are stimulated by anionic phospholipid-mimetic citrate ions that bind near a site where the N-terminus splits from the protein core [#14], while cytochrome b5 can modulate isoform-specific intrinsic clearance [#22]. The enzyme metabolizes endogenous vitamin D metabolites, and a gain-of-function substrate-recognition-site mutation (I301T) accelerates 1,25-dihydroxyvitamin D inactivation and causes vitamin D-dependent rickets type 3 [#7]. CYP3A4 is also subject to mechanism-based inactivation, forming a metabolic-intermediate complex with verapamil/norverapamil and apoprotein adducts from a raloxifene diquinone methide intermediate [#12, #15]. Transcription is governed by an interlocking nuclear-receptor network — PXR, CAR, GR, and VDR acting through proximal and distal (XREM, −7.2 to −7.8 kb) elements, with HNF4α binding required to license PXR/CAR activation and a distal regulatory region physically looping to the promoter as a shared CYP3A enhancer [#0, #1, #10, #11, #20] — and is further tuned by circadian DBP/E4BP4, p53, and post-transcriptional miR-27b targeting of the 3'-UTR [#9, #16, #8]. Functionally important variation includes the splicing-defective CYP3A4*22 allele that lowers hepatic expression and the heme-null, catalytically dead CYP3A4*20 allele that reduces in vivo drug clearance [#2, #3, #6].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that CYP3A4 induction is driven by ligand-activated nuclear receptors, resolving how xenobiotics and glucocorticoids upregulate the enzyme.\",\n      \"evidence\": \"Reporter assays with the −1 kb CYP3A4 promoter and separate/combined GR and PXR transfection in HepG2 cells\",\n      \"pmids\": [\"10772626\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not localize the GR/PXR response elements within the promoter\", \"Receptor cooperativity in vivo not addressed\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined how coding variants alter catalytic competence, linking specific residues to turnover and heme incorporation.\",\n      \"evidence\": \"Site-directed mutagenesis with bacterial heterologous expression and steroid/midazolam/chlorpyrifos activity assays\",\n      \"pmids\": [\"11714865\", \"11470997\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Allele frequencies and in vivo clinical impact not established\", \"Structural basis of altered kinetics not resolved\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Mapped CAR response elements in the CYP3A4 5'-flanking region and showed CAR/PXR share these motifs, revealing cooperative receptor regulation.\",\n      \"evidence\": \"Reporter assays and binding-motif identification at −7720 and −150, with in vivo confirmation\",\n      \"pmids\": [\"12130689\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative contribution of each motif to inducibility not resolved\", \"Cofactor requirements not addressed here\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identified HNF4α as a required gatekeeper licensing PXR/CAR-mediated activation, and defined the distal (>−3.2 kb / XREM) region needed for constitutive and inducible expression.\",\n      \"evidence\": \"Reporter assays, EMSA, Hnf4α conditional knockout mice, and CYP3A4/lacZ transgenic mice with deletion analysis\",\n      \"pmids\": [\"12514743\", \"12815159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which HNF4α permits receptor action not detailed\", \"Chromatin architecture of the XREM not resolved at this stage\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Demonstrated isoform-selective mechanism-based inhibition, showing verapamil metabolites trap CYP3A4 (but not CYP3A5) as a metabolic-intermediate complex.\",\n      \"evidence\": \"Dual-beam spectrophotometry detecting the 455 nm MIC and time-dependent inactivation kinetics with recombinant CYP3A4/CYP3A5 and liver microsomes\",\n      \"pmids\": [\"15689501\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of CYP3A4 vs CYP3A5 selectivity not resolved\", \"In vivo drug-interaction magnitude not quantified\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Connected a null allele to clinical phenotype and confirmed CYP3A4 as a bioactivating enzyme for a prodrug.\",\n      \"evidence\": \"CYP3A4*20 expression in yeast/HEK293 showing no heme incorporation plus in vivo midazolam pharmacokinetics; CYP isoform panel and antibody inhibition for pradefovir activation\",\n      \"pmids\": [\"16580902\", \"16940083\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"*20 carrier numbers very small\", \"Determinants of heme incorporation failure not defined\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Revealed circadian control of CYP3A4, explaining ~24 h oscillation in drug-metabolizing capacity.\",\n      \"evidence\": \"Reporter assays, EMSA confirming DBP binding near the TSS, and E4BP4 repression in serum-shocked HepG2 cells\",\n      \"pmids\": [\"18004209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo rhythmicity of human CYP3A4 not directly demonstrated here\", \"Integration with nuclear-receptor inputs unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Added a post-transcriptional layer, showing miR-27b directly and indirectly (via VDR) suppresses CYP3A4.\",\n      \"evidence\": \"Luciferase 3'-UTR reporters with MRE mutagenesis, immunoblot, qPCR, and miR-27b overexpression\",\n      \"pmids\": [\"19581388\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological miR-27b levels required for regulation not defined\", \"Single-lab reporter-based mechanism without in vivo confirmation\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established CYP3A4*22 as an expression-reducing regulatory allele acting through aberrant splicing, and quantified substrate-dependent effects of other coding alleles.\",\n      \"evidence\": \"Allelic expression in human liver, minigene transfection, clinical pharmacokinetics, plus Sf21 recombinant kinetics for *16 and *18 across seven substrates\",\n      \"pmids\": [\"20386561\", \"20847137\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Splice mechanism tissue-specificity not yet shown at this stage\", \"Generalizability of substrate-dependent effects across all substrates unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Resolved the chemical mechanism of raloxifene-mediated inactivation, distinguishing dehydrogenation from oxygenation.\",\n      \"evidence\": \"18O-incorporation tracing and mass spectrometry in reconstituted CYP3A4\",\n      \"pmids\": [\"20405834\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the modified apoprotein carboxylate residue not defined\", \"Quantitative contribution to clinical inactivation not assessed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Expanded the regulatory network to stress and intestinal/seasonal signals, implicating p53 and VDR in CYP3A4 expression.\",\n      \"evidence\": \"ChIP and reporter assays for p53 binding in hepatocytes; VDR genotyping with intestinal biopsy expression and midazolam pharmacokinetics\",\n      \"pmids\": [\"23054612\", \"22484315\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiological relevance of chemotherapy-induced p53 effect uncertain\", \"Causality of VDR genotype-expression association not proven\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Provided a structural and mechanistic account of allosteric stimulation by anionic effectors, mapping rate-limiting electron-transfer steps.\",\n      \"evidence\": \"X-ray co-crystallization of CYP3A4 with progesterone and citrate plus functional reconstitution of soluble CYP3A4/CPR\",\n      \"pmids\": [\"26066995\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological identity of the in vivo anionic activator not established\", \"Quantitative contribution to hepatic activity unknown\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Demonstrated a gain-of-function disease mechanism, linking an SRS-4 mutation to accelerated vitamin D inactivation and Mendelian rickets.\",\n      \"evidence\": \"Whole exome sequencing and in vitro activity comparison of I301T mutant vs wild-type toward vitamin D metabolites\",\n      \"pmids\": [\"29461981\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural mechanism described from modeling, not solved structure\", \"Single-case basis for the disease association\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Established physical promoter-enhancer looping at a distal regulatory region shared across the CYP3A locus and tied DRR SNPs to expression.\",\n      \"evidence\": \"4C chromatin conformation capture, CRISPR deletion, reporter assays, and human liver cohort (n=246)\",\n      \"pmids\": [\"36045613\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Trans-factors binding the DRR not identified\", \"Mechanism connecting DRR to nuclear-receptor inputs unresolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Refined the mechanism of small-molecule modulation of PXR-driven CYP3A4 induction via chaperone exchange and coactivator interactions.\",\n      \"evidence\": \"Co-IP of PXR with HSP90α and RXRα, immunofluorescence for nuclear translocation, qPCR/western with hCAR siRNA\",\n      \"pmids\": [\"35417848\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single-lab co-IP without orthogonal interaction validation\", \"Generalization beyond the tested ligand unclear\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How the multiple regulatory inputs (HNF4α, PXR/CAR, GR, VDR, p53, circadian DBP/E4BP4, miRNAs, and the distal regulatory region) are integrated at chromatin to set CYP3A4 expression in a given hepatocyte remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking enhancer looping to specific trans-factor occupancy\", \"Quantitative hierarchy among regulatory inputs unknown\", \"In vivo human dynamics of post-transcriptional vs transcriptional control undefined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016491\", \"supporting_discovery_ids\": [4, 7, 14, 24]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [15, 18]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [14, 22]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-9748784\", \"supporting_discovery_ids\": [12, 13, 18, 24]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [4, 7]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"POR\", \"CYB5A\", \"PXR\", \"CAR\", \"HNF4A\", \"VDR\", \"RXRA\", \"HSP90AA1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}